LOS ANGELES, July 18, 2024 /PRNewswire/ — Eyenuk, a global artificial intelligence (AI) digital health company and leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced the appointment …
Eyenuk Appoints Bryan Haardt as Chief Executive Officer Read More »
Eyenuk Names Paul Praino Interim Chief Executive Officer
Company Founder Kaushal Solanki Steps Down as CEO, Remains Strategic Advisor and Board Member
Eyenuk Names Paul Praino Interim Chief Executive Officer Read More »
LOS ANGELES, November 28th, 2023 – Eyenuk, Inc., a leading global digital health company specializing in artificial intelligence (AI), today stands shoulder to shoulder with the National Eye Institute (NEI), …
This clearance expands the label of its flagship product, the EyeArt® AI system, broadening the choice for primary care clinics to screen people with diabetes Company’s FDA clearance also includes …
Leads Expansion of Commercial Team Toward Next Stage of Growth LOS ANGELES – February 16, 2023 – Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in …
Eyenuk Welcomes Paul Praino as Chief Commercial Officer Read More »
The approval allows Eyenuk’s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31, …
Rising Star Clinical Diagnostic Tool Category Eyenuk has been named a finalist in the Rising Star Clinical Diagnostic Tool category of the UCSF Digital Health Awards. Produced by the University …
Eyenuk named 2022 UCSF Digital Health Awards Finalist Read More »
Brings Eyenuk’s total funding to over $43 million Funding round led by AXA IM Alts; joined by T&W Medica A/S, Kendall Capital Partners, and others Eyenuk adds three new board …
Academic leaders will review their experience with the technology during a symposium at AAO 2022, the American Academy of Ophthalmology annual meeting CHICAGO, September 30, 2022 — From the American …
Program selects Eyenuk’s EyeArt AI system to make vision-saving screening more accessible in remote Ontario communities LOS ANGELES and TORONTO, August 16, 2022 – Vision Loss Rehabilitation Canada (VLRC), Canada’s …
LOS ANGELES, June 8, 2022 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI …
LOS ANGELES, June 1, 2022 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI …
May 17, 2022 – Meritus Health, the largest provider of healthcare in western Maryland, recently adopted the EyeArt® artificial intelligence (AI) system for autonomous diabetic retinopathy testing in its primary …
Meritus Health Adopts the EyeArt® AI System for Autonomous Diabetic Eye Testing Read More »
March 28, 2022 – Eyenuk was recently featured in a Medical Tribune article highlighting the need for autonomous artificial intelligence (AI) systems for regular diabetic eye testing. In this article, …
March 21, 2022 – University of Utah Health, provider of care to patients in Utah and the broader Mountain West region and home to the only academic medical center in …
University of Utah Implements the EyeArt® AI System for Autonomous Diabetic Eye Testing Read More »
Harnessing Artificial Intelligence, Eyenuk is Focused on Improving Population Health Outcomes by Bringing Diabetes Complication Management to Point-of-Care and Community Settings WASHINGTON, March 10, 2022 – Population Health Alliance …
January 28, 2022 – Today, Frank Cheng, Eyenuk President and CCO, presented in the Collaborative Community on Ophthalmic Imaging (CCOI) 2022 Virtual Conference. In his presentation during a session focused …
A new diabetic retinopathy screening benefit enabled by the EyeArt® AI system is made available by Discovery Health, a global leader in Healthcare and Financial Services LOS ANGELES, December 7, …
Eyenuk Launches EyeArt AI System in South Africa in Collaboration with Discovery Health Read More »
The published results demonstrate exceptional EyeArt accuracy in a pre-registered, prospective, multicenter clinical trial Los Angeles, November 15, 2021 — Eyenuk, Inc., a global artificial intelligence (AI) medical technology and …
The CMS Final Rule establishes a national payment for CPT code 92229 that describes Eyenuk’s FDA-cleared EyeArt® AI system and confirms that AI can be used to close care gaps …
